Key Developments: Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

52.36USD
23 Oct 2014
Price Change (% chg)

$0.52 (+1.00%)
Prev Close
$51.84
Open
$52.01
Day's High
$52.36
Day's Low
$52.01
Volume
112,863
Avg. Vol
1,449,845
52-wk High
$57.49
52-wk Low
$46.32

Search Stocks

Latest Key Developments (Source: Significant Developments)

Leica Biosystems and Bristol-Myers Squibb enter into a development and commercialization collaboration
Thursday, 7 Aug 2014 11:00am EDT 

Leica Biosystems:Enters an agreement with Bristol-Myers Squibb company to collaborate on developing companion diagnostics on theLeica BOND system for use as aid in selecting patients for treatment with certain pharmaceuticals developed, or to be developed, by Bristol-Myers Squibb.Other terms of agreement were not disclosed.  Full Article

Allied Minds PLC and Bristol Myers Squibb form new enterprise to advance discoveries of biopharmaceutical innovations at U.S academic research institutions
Monday, 4 Aug 2014 02:00am EDT 

Allied Minds PLC:Allied Minds PLC and Bristol-Myers Squibb Company announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise.Says it is created to identify and foster research and pre-clinical development of biopharmaceutical innovations from university research institutions across the U.S.Allied-Bristol Life Sciences LLC will focus on efficiently and effectively converting discoveries from university research institutions into therapeutic candidates for clinical development, and ultimately approved therapies that address serious diseases.Says for programs identified by the new enterprise, university researchers will be able to access Bristol-Myers Squibb's drug discovery research expertise, and Allied Minds' financial and management experience.  Full Article

European Commission approves Bristol-Myers Squibb Co's Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and Prevention of Recurrent DVT and PE
Tuesday, 29 Jul 2014 07:00am EDT 

Bristol-Myers Squibb Co:Says the company and Pfizer Inc announces that the European Commission has approved Eliquis for the treatment of DVT and PE, and the prevention of recurrent DVT and PE in adults.The European Commission approval applies to all European Union (EU) member states as well as Iceland and Norway.Eliquis is also approved in the EU for the prevention of venous thromboembolism (VTE) in adults who have undergone elective total hip or knee replacement surgery.  Full Article

Bristol-Myers Squibb reaffirms FY 2014 EPS guidance
Thursday, 24 Jul 2014 07:32am EDT 

Bristol-Myers Squibb Co:Adjusts FY 2014 GAAP EPS guidance range from $1.70 - $1.80 to $1.50 - $1.60 as a result of impairment and expected additional restructuring charges.Confirms non-GAAP EPS guidance range of $1.70 - $1.80.FY 2014 non-GAAP EPS of $1.77 - Thomson Reuters I/B/E/S.  Full Article

Bristol-Myers Squibb Co and Ono Pharmaceutical Co., Ltd. announces strategic immuno oncology collaboration in Japan, South Korea and Taiwan
Wednesday, 23 Jul 2014 09:30pm EDT 

Bristol-Myers Squibb Co:Says Ono Pharmaceutical Co., Ltd. signs a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan.Says as part of the agreement, Bristol-Myers Squibb and Ono will jointly develop and commercialize Opdivo (nivolumab) and Yervoy (ipilimumab) across a broad range of tumor types.Bristol-Myers Squibb and Ono will jointly pursue development of monotherapy and combination regimens, with Opdivo as the foundational therapy in Japan, South Korea and Taiwan, and leverage global clinical trials by including patients from the three countries.  Full Article

Bristol-Myers Squibb announces plans for third quarter submission of Biologics License Application for Opdivo
Thursday, 10 Jul 2014 07:30am EDT 

Bristol-Myers Squibb Co:Plans a third quarter submission of a Biologics Licensing Application (BLA) for Opdivo ( (reg) )(nivolumab) for previously treated advanced melanoma.Proposed the name Opdivo (pronounced op-dee-voh), which, if approved by health authorities, will serve as the trade name for nivolumab.  Full Article

Bristol-Myers Squibb Co announces Japan approves Daklinza (daclatasvir) and Sunvepra (asunaprevir) Dual Regimen
Monday, 7 Jul 2014 07:00am EDT 

Bristol-Myers Squibb Co:Says Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Daklinza(daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor ( in vitro ) and Sunvepra (asunaprevir), a NS3/4A protease inhibitor.Says providing new treatment that can lead to cure for many patients in Japan who have no treatment options.Says Daklinza+Sunvepra Dual Regimen is Japan's first all-oral, interferon- and ribavirin-free treatment regimen for patients with genotype 1 chronic hepatitis C virus (HCV) infection, including those with compensated cirrhosis.  Full Article

Bristol-Myers Squibb Co receives positive CHMP opinion for Daklinza (daclatasvir) for treatment of Chronic Hepatitis C in European Union
Friday, 27 Jun 2014 07:00am EDT 

Bristol-Myers Squibb Co:Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency (EMA) has adopted positive opinion.Says recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products.Says for treatment of chronic hepatitis C virus (HCV) infection in adults.This is the first positive opinion given by the CHMP for an NS5A complex inhibitor and will be reviewed by the European Commission, which has the authority to approve medicines for the European Union.  Full Article

Bristol-Myers Squibb Co and Pfizer Inc announces Eliquis (apixaban) receives CHMP positive opinion for treatment of Deep Vein Thrombosis and Pulmonary Embolism and Prevention of Recurrent DVT and PE
Friday, 27 Jun 2014 07:00am EDT 

Bristol-Myers Squibb Co and Pfizer Inc:Says Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinion.Says recommending that Eliquis (apixaban) be granted marketing authorization for treatment of DVT (deep vein thrombosis) and PE (pulmonary embolism), and the prevention of recurrent DVT and PE, in adults.Says CHMP's positive opinion will be reviewed by the European Commission (EC).Says decision on whether to approve Eliquis for this indication will be made by the EC and will be applicable to all European Union member states plus Iceland and Norway.Positive opinion was based on the results from the pivotal AMPLIFY and AMPLIFY-EXT studies.AMPLIFY, a randomized, double-blind, multicenter trial, included 5,395 patients with confirmed symptomatic DVT or PE requiring treatment for six months and evaluated Eliquis therapy compared to standard of care.Says primary efficacy endpoint was the composite endpoint of recurrent symptomatic VTE (nonfatal DVT or nonfatal PE) or VTE-related death.Says primary safety endpoint was the incidence of major bleeding compared to standard of care.  Full Article

Bristol-Myers Squibb Co announces dividend
Tuesday, 17 Jun 2014 04:30pm EDT 

Bristol-Myers Squibb Co:Declared a quarterly dividend of $0.36 per share on the $.10 par value Common Stock of the corporation.Next quarterly dividend will be payable on Aug. 01, 2014, to stockholders of record at the close of business on July 3, 2014.  Full Article

ConvaTec owners appoint banks to explore sale: sources

LONDON - ConvaTec's owners have appointed Morgan Stanley and Goldman Sachs to explore a sale of the medical device maker which could be worth up to $10 billion, sources familiar with the matter said.

Search Stocks